Stratos Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $271K | Buy |
+5,565
| New | +$271K | 0.01% | 567 |
|
|
2025
Q1 | – | Sell |
-5,440
| Closed | -$214K | – | 677 |
|
|
2024
Q4 | $214K | Sell |
5,440
-2
| -0% | -$79 | 0.01% | 664 |
|
|
2024
Q3 | $256K | Sell |
5,442
-1,366
| -20% | -$64.2K | 0.01% | 646 |
|
|
2024
Q2 | $368K | Buy |
6,808
+25
| +0.4% | +$1.35K | 0.02% | 537 |
|
|
2024
Q1 | $462K | Sell |
6,783
-82
| -1% | -$5.59K | 0.03% | 476 |
|
|
2023
Q4 | $430K | Sell |
6,865
-3,696
| -35% | -$231K | 0.02% | 489 |
|
|
2023
Q3 | $479K | Buy |
10,561
+4,886
| +86% | +$222K | 0.03% | 434 |
|
|
2023
Q2 | $319K | Buy |
5,675
+105
| +2% | +$5.9K | 0.02% | 503 |
|
|
2023
Q1 | $252K | Buy |
5,570
+129
| +2% | +$5.84K | 0.02% | 528 |
|
|
2022
Q4 | $221K | Buy |
+5,441
| New | +$221K | 0.02% | 531 |
|